BRDS, ELUT and DTOC among pre-market losers

seekingalpha2023-09-20

Losers: ARS Pharmaceuticals (SPRY) -60% FDA declined to approve its epinephrine nasal spray Seelos Therapeutics (SEEL) -59% announces top line results from SLS-002 phase II study in adults with major...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2368883196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-09-20 20:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2368883196","market":"us","top_or_hot":-1,"title":"BRDS, ELUT and DTOC among pre-market losers","media":"seekingalpha","content":"<div>\n<p>Losers: ARS Pharmaceuticals (SPRY) -60% FDA declined to approve its epinephrine nasal spray\n\nSeelos Therapeutics (SEEL) -59% announces top line results from SLS-002 phase II study in adults with major...</p>\n\n<a href=\"https://seekingalpha.com/news/4013574-brds-elut-and-dtoc-among-pre-market-losers\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRDS, ELUT and DTOC among pre-market losers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRDS, ELUT and DTOC among pre-market losers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-20 20:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4013574-brds-elut-and-dtoc-among-pre-market-losers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Losers: ARS Pharmaceuticals (SPRY) -60% FDA declined to approve its epinephrine nasal spray\n\nSeelos Therapeutics (SEEL) -59% announces top line results from SLS-002 phase II study in adults with major...</p>\n\n<a href=\"https://seekingalpha.com/news/4013574-brds-elut-and-dtoc-among-pre-market-losers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELUT","symbol_name":"Elutia","start_time":0,"source_url":"https://seekingalpha.com/news/4013574-brds-elut-and-dtoc-among-pre-market-losers","article_id":"2368883196","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2368883196","pubTimestamp":1695212176,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Losers: ARS Pharmaceuticals -60%FDA declined to approve its epinephrine nasal spray. Seelos Therapeutics -59%announces top line results from SLS-002 phase II study in adults with major depressive disorder at imminent risk of suicide.Sunnova Energy International -7%announces proposed private offering of $400 million notes.Gorilla Technology Group -6%announces $25 Million registered direct offering of convertible preferred stock.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELUT":"Elutia","AONC":"American Oncology Network, Inc.","SEEL":"Seelos Therapeutics, Inc.","BK4022":"陆运","BK4585":"ETF&股票定投概念","BK4561":"索罗斯持仓","BK4133":"新能源发电业者","BK4230":"旅客陆运","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","SPRY":"ARS PHARMACEUTICALS INC","BK4023":"应用软件","LU0823414478.USD":"法巴经典能源转换基金","GRRR":"Gorilla Technology","BRDS":"Bird Global","BK4139":"生物科技","BK4007":"制药","NOVA":"Sunnova Energy International Inc."},"translate_title":"BRDS、ELUT和DTOC在盘前输家中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRDS":1,"SPRY":1,"SEEL":1,"NOVA":1,"GRRR":1,"ELUT":1,"DTOC":1,"AONC":1},"content_text":"Losers: ARS Pharmaceuticals (SPRY) -60% FDA declined to approve its epinephrine nasal spray\n\nSeelos Therapeutics (SEEL) -59% announces top line results from SLS-002 phase II study in adults with major depressive disorder at imminent risk of suicide.\nBird Global (BRDS) -20%.\nElutia (ELUT) -16%.\nDigital Transformation Opportunities Corp. (DTOC) -10%.\nSunnova Energy International (NOVA) -7% announces proposed private offering of $400 million notes.\nGorilla Technology Group (GRRR) -6% announces $25 Million registered direct offering of convertible preferred stock.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2368883196"}